ValiRx Regulatory News (VAL)

29 Jul 2009 08:06



ValiRx plc

("ValiRx" or the "Company")

Australian patent acceptance for lead GeneICE compound

The Company is pleased to announce that it has received acceptance from the Australian Patent Office for the patent application relating to the Company's lead cancer compound, VAL 101, which is derived from the GeneICE technology platform for gene silencing.

Provided there is no opposition the full patent is anticipated to be issued in due course.

ValiRx holds the rights to GeneICE through its wholly owned subsidiary, ValiPharma Ltd, which has an exclusive worldwide license agreement with Imperial College Innovations Limited. GeneICE compounds have the potential to freeze the development and growth of cancerous cells and also have potential major applications in inflammatory disease and inherited genetic conditions. 

Previous results have shown VAL 101's efficacy in several cell-based cancer models, including prostate, ovarian and pancreatic cancers in vitro.

Commenting on the patent acceptance, Dr Satu Vainikka, Chief Executive Officer of the Company, said, "We are very pleased to have received this patent acceptance, which adds to our portfolio of previous patent grants. The VAL 101 compound has previously shown its ability in killing several cancers and preclinical trials are progressing with our research partners."

For further information please contact: